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Abstract
The 2009 flu pandemic and the appearance of oseltamivir-resistant H1N1 influenza strains highlight the need for treatment
alternatives. One such option is the creation of a protective physical barrier in the nasal cavity. In vitro tests demonstrated
that iota-carrageenan is a potent inhibitor of influenza A virus infection, most importantly also of pandemic H1N1/2009 in
vitro. Consequently, we tested a commercially available nasal spray containing iota-carrageenan in an influenza A mouse
infection model. Treatment of mice infected with a lethal dose of influenza A PR8/34 H1N1 virus with iota-carrageenan
starting up to 48 hours post infection resulted in a strong protection of mice similar to mice treated with oseltamivir. Since
alternative treatment options for influenza are rare, we conclude that the nasal spray containing iota-carrageenan is an
alternative to neuraminidase inhibitors and should be tested for prevention and treatment of influenza A in clinical trials in
humans.
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Introduction
While the current H1N1 influenza (flu) pandemic was ongoing in
2010, efforts were made to develop new antiviral agents for
influenzatreatment that possess an improved spectrum of activity or
better pharmacologic profiles, compared to current treatments. The
medical need for the development of new antiviral agents for the
treatment of influenza virus-infected patients is mainly based on
increasing resistance against currently approved drugs and on their
limited antiviral efficacy in severe cases of influenza [1]. Available
anti-influenza drugs target two different steps of the viral life cycle,
the uncoating and the release of virus particles from infected cells.
Uncoating of influenza A viruses is induced by the viral M2 ion
channel protein and can be blocked by the adamantane-based
compounds amantadine and rimantadine [2,3]. Although clinically
effective, these drugs caused considerable gastrointestinal and
neurological side-effects in patients [4]. Moreover, emerging
resistant influenza A viruses during seasonal influenza epidemics
have been observed [5]. Today, the resistance level to amantadine
has reached nearly 100% for H3N2-type influenza A virus strains,
but resistant mutants are also frequently found among seasonal
H1N1 isolates [1,6]. Therefore, adamantanes are not considered
anymore for routine use, but might be an option when all other
measures fail [7]. The more recently approved antiviral agents to
treat influenza infections are the neuraminidase inhibitors zanami-
vir and oseltamivir, both developed by rational drug design [8].
Influenza virus neuraminidase (NA) is anchored in the viral
membrane and cleaves sialic acid-containing receptors on the
surface of infected cells and on progeny virions. This enzymatic
activity facilitates the movement of virus particles through the upper
respiratory tract aswell asthe release (budding) of newly synthesized
virions from infected cells [9]. Although highly efficacious in vitro
[10] and in animal models [11,12], in clinical trials neuraminidase
inhibitors showed lower than expected efficacy against influenza
symptoms in otherwise healthy adults [13]. However, in children
with laboratory confirmed influenza, neuraminidase inhibitors were
effective in reducing illness duration if given within 48 hours post
exposure, but their efficacy in reducing severe complications in ‘at
risk’ children, e.g. with asthma, awaits further investigation [14,15].
Nonetheless, neuraminidase inhibitors have been used successfully
as antiviral chemoprophylaxis for preventing and reducing the
symptoms of seasonal influenza [16,17]. Accordingly, in many
countries neuraminidase inhibitors are stockpiled as means to
prevent a worldwide pandemic [18,19]. However, alternative
treatment options are urgently needed as the current choice of
drugs is limited and resistance is a constant threat [20].
One alternative approach to prevention and treatment of
influenza is the creation of a protective physical barrier in the nasal
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polysaccharides derived from red seaweed (Rhodophyceae). Three
main forms of carrageenans have been identified: kappa (k), iota
(i), and lambda (l). They differ from each other in sulphation
degree, solubility and gelling properties [21]. Carrageenan is in
widespread commercial use as an additive contributing to the
texture and stability of various processed foods and cosmetic
products, including some brands of sexual lubricant. Since high-
quality carrageenan preparations (reviewed in [22]) appear to have
a good safety profile for long-term use [23] and can inhibit HIV
infections in model systems [24], clinical studies were conducted to
validate the usefulness of carrageenan (Carraguard) as a vaginal
microbicide for the prevention of HIV-1 transmission [24,25].
Reasons for the failure of these studies are manifold and
approaches to improve the efficacy of such topical formulations
are in the focus of current research [26]. The antiviral potential of
carrageenan and other sulphated polysaccharides in vitro against
infections by several enveloped viruses such as herpes simplex virus
(HSV-1 and HSV-2), human cytomegalovirus (HCMV), vesicular
stomatitis virus (VSV), Sindbis virus, and human immunodefi-
ciency virus has been described more than 20 years ago [27,28],
and has been reviewed recently [29–31]. Newer studies have
confirmed the efficacy of carrageenans from different marine algal
species in animal models of HSV and CMV infections in vivo [32–
34]. The inhibitory mechanism of carrageenans on virus
replication seems to comprise early events of the infection cycle,
i.e. attachment and entry of virus particles [35,36], and is
dependent on the type of polysaccharide [29] as well as the
serotype of the virus and the host cells [37].
Iota-carrageenan has been reported to inhibit the infection of
certain non-enveloped human viral pathogens, e.g. human
hepatitis A (HAV) and papilloma viruses (HPV) in vitro [37,38].
Moreover, iota-carrageenan interfered specifically with the
adsorption of HPV16 capsids to human sperm cells [39]. These
findings encouraged the authors to propose clinical trials in order
to determine whether carrageenan-based products are effective as
topical microbicides against genital HPVs [38]. We recently could
show that iota-carrageenan is a potent anti-rhinoviral substance in
vitro and thus an ideal candidate for the treatment of infections
that predominantly occur in the nasal cavity and upper respiratory
tract [40]. Therefore, we were interested whether carrageenans
and in particular iota-carrageenan have any antiviral activity
against human influenza A viruses.
Results
Iota-carrageenan inhibits influenza virus-induced plaque
formation on MDCK cells
We determined the sensitivity of the influenza virus strain H1N1
(A/PR8/34) and the formerly pandemic H3N2 (A/Aichi/2/68) to
carrageenans of subtypes iota and kappa by plaque reduction
assays in MDCK cells [41,41]. The results are summarized in
Table 1. The two carrageenan types inhibited plaque formation of
both viruses tested although to a varying degree. Iota-carrageenan
was the most active substance in all experiments followed by
kappa-carrageenan. The purity of iota- as well as kappa-
carrageenan preparations analyzed by nuclear magnetic resonance
spectroscopy (NMR) was greater than 95% and the molecular
weight of both polymers well over 1009000 (data not shown).
Nevertheless, the inhibitory potential of iota-carrageenan with
IC50 values of around 0.2 mg/ml in H1N1 and 0.04 mg/ml in
H3N2 infections was up to 10 times higher compared to kappa-
carrageenan (Table 1). Generally, plaque formation by H3N2
viruses was inhibited at lower carrageenan concentrations when
compared to H1N1. CMC, the control polymer, did not show any
inhibitory effect up to the highest concentrations tested (400 mg/
ml). No cytotoxicity of any of the polymers at the highest dosages
was observed.
Iota-carrageenan promotes survival of influenza
virus-infected MDCK cells and inhibits viral replication
MDCK cells were infected at low multiplicity (MOI=0.01)
with H1N1 A/PR/8/34 or H3N2 A/Aichi/2/68 virus in the
presence of various concentrations of iota-carrageenan or CMC.
After 48 hours, cell viability was determined with a standard cell
proliferation test. A typical result obtained by this assay is shown
in Figure 1. For instance, iota-carrageenan at a concentration of
4 mg/ml reduced the cytopathic effect of the A/PR/8/34 virus
by more than 50% compared to control polymer CMC
(Figure 1A). For cells infected with the A/Aichi/2/68 H3N2
virus, a concentration of 0.4 mg/ml of iota-carrageenan was
sufficient to protect 50% of the cells from virus-induced cell
death (Figure 1B).
In line with these findings, we have also determined the effect
over time of different iota-carrageenan concentrations on viral
replication of infected MDCK cells (Figure 1C–F). In marked
contrast to the control polymer CMC, iota-carrageenan at
concentrations of 40 and 4 mg/ml very efficiently reduced viral
replication by 2–4 logs up to 96 hours post infection. Thus, iota-
carrageenan efficiently promotes survival of influenza A-infected
MDCK cells and does so by directly reducing the amount of virus
released from infected cells.
Iota-carrageenan promotes survival of influenza
A/PR/8/34 virus-infected primary human nasal epithelial
cells (HNep)
HNep cells were infected with influenza virus (5 PFU/cell) in
the presence of iota-carrageenan or CMC as a control polymer
and subsequently maintained in medium containing different
amounts of polymers (0.5 mg/ml to 400 mg/ml). After 48 hours,
cell proliferation was determined with a Resazurin-based in vitro
toxicology assay. As shown in Figure 2, iota-carrageenan-treated
cells showed significantly better protection from virus-induced cell
death than cells treated with CMC at all concentrations tested.
This result shows that iota-carrageenan promotes survival of
influenza A virus-infected HNep cells.
Iota-carrageenan is active against pandemic H1N1/2009
influenza virus in vitro
Since the A/PR/8/34 and A/Aichi/2/68 viruses were isolated
several decades ago, we were interested whether iota-carrageenan
bears antiviral activity also against the novel pandemic H1N1/
2009 strain [18]. Similar to experiments with seasonal influenza
virus strains, iota-carrageenan was found to strongly inhibit plaque
formation of the pandemic H1N1/2009 strain in MDCK cells
Table 1. Inhibitory effects of polysaccharide compounds.
Virus IC50
* iota IC50 kappa IC50 CMC
A/Aichi/2/68 H3N2 0.04 0.30 .400
A/PR8/34 H1N1 0.20 2.70 .400
*Inhibitory concentration 50%: concentration in mg/ml required to inhibit
influenza virus plaque formation on MDCK cells. Each value represents the
mean of a quadruplicate assay.
doi:10.1371/journal.pone.0014320.t001
H1N1 Inhibition by Carrageenan
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IC50 values indicate that iota-carrageenan had the same antiviral
potency against the pandemic H1N1/2009 strain as compared to
the A/Aichi/2/68 H3N2 virus while inhibition of the A/PR8/34
H1N1 virus required five times higher concentrations of iota-
carrageenan, at least in MDCK cells.
Influenza A virus binding to iota-carrageenan beads is
inhibited by dissolved iota-carrageenan but not by a
control polymer
Several published reports indicate that the principal mecha-
nism by which carrageenans block virus infectivity is by direct
binding to the viral surface [35,36,38,40]. In order to investigate
whether a similar mechanism holds true for influenza viruses, we
incubated iota-carrageenan-coated agarose beads with influenza
A/PR/8/34 viral particles that were previously labelled with the
fluorescent dye Alexa Fluor 488 (H1N1-A488). We found that
the fluorescent virus directly binds to iota-carrageenan beads but
not to agarose carrier material (Figure 4C, D). Importantly,
binding of virus to iota-carrageenan was specific, as it was
abolished in the presence of excess iota-carrageenan (Figure 4E),
but not CMC (Figure 4F). Likewise, we independently confirmed
this observation by using the same fluorescently-labelled H1N1
viral particles in FACS experiments with MDCK cells in the
presence of iota-carrageenan or control polymer CMC. As
shown in Figures 4G–I, only iota-carrageenan specifically
competed with virus binding to MDCK cells but not CMC.
Figure 1. Iota-carrageenan promotes cell viability and reduces viral titer of influenza A-infected MDCK cells. MDCK cells grown in 96-
well plates were infected with H1N1 A/PR/8/34 virus (A) and H3N2 A/Aichi/2/68 virus (B) (0.01 PFU/cell) in the presence of carrageenans (iota-
carrageenan black diamonds, kappa-carrageenan black squares) at concentrations as indicated on the x-axis in mg/ml. Plates were incubated at 37uC
until cells in the control (no polymer added) showed .90% damage. Cell proliferation was determined with a Resazurin-based in vitro toxicology
assay. Samples were measured fluorometrically by monitoring the increase in fluorescence at a wavelength of 590 nm using an excitation
wavelength of 544 nm. Values obtained from mock-infected cells were set to 100%, and the values of cells infected in the absence of polymer were
set to 0% (y-axis). (C)-(F) MDCK cells were infected with H1N1 A/PR/8/34 as before and further kept in the presence of iota-carrageenan (circles) or the
control polymer CMC (squares) at indicated concentrations and 24 (C), 48 (D), 72 (E), and 96 hours (F) post infection, respectively. Supernatants were
harvested, pooled, and subsequently used to determine the TCID50/ml according to the method of Reed and Muench [59]. The points represent the
mean of a quadruplicate experiment, the standard deviation is indicated.
doi:10.1371/journal.pone.0014320.g001
H1N1 Inhibition by Carrageenan
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carrageenan is conferred through direct binding of polymer to
viral particles.
Iota-carrageenan inhibits attachment of A/PR/8/34
influenza virus to cells
To explore further the antiviral mode of action of iota-
carrageenan, we performed time of addition studies in vitro.
Therefore, iota-carrageenan was added to MDCK cells either
before, after, or simultaneously with virus inoculum. The state of
infection was analysed by plaque reduction assays (Figure 5, A and
B) or alternatively, microscopically by staining the viral nucleo-
protein (NP) with a monoclonal antibody (Figure 5, C and D). If
iota-carrageenan was added to cells prior to infection, no positive
effect on plaque reduction could be observed. Importantly, pre-
incubation of cells with iota-carrageenan up to 48 hours was not
toxic or altered proliferation of the cells in any way (data not
shown). However, virus attachment to cells and hence, infection
was dose-dependently blocked if iota-carrageenan was mixed with
virus particles before addition to cells as evidenced in a reduction
of formed plaques formed in MDCK cells and compared to
control polymer (Figure 5A). Similar results were obtained with
Vero cells (data not shown). In sharp contrast, if virus was allowed
to adsorb to cells before addition of iota-carrageenan no protective
effect on plaque formation similar to the control polymer CMC
was observed (Figure 5B). When internalization of virus was
assessed by immunofluorescence staining using an anti-NP
antibody, infection of cells was only efficiently prohibited if virus
was adsorbed in the presence of iota-carrageenan but not control
polymer (Figure 5C) or if iota-carrageenan or control polymers
were added post-adsorption (Figure 5D). In summary, iota-
carrageenan inhibits influenza virus infection by directly interact-
ing with virus particles thereby preventing adsorption to cellular
receptors and subsequent internalization.
Intranasal iota-carrageenan application significantly
supports survival of mice infected with H1N1 A/PR/8/34
influenza virus
The pathogenicity of influenza viruses in mice varies and is
dependent on the strain and its adaptation to its host. Depending
on virus dose and strain, influenza virus can induce lethal
infections in certain mouse strains usually within two weeks [42].
To investigate whether iota-carrageenan is efficacious in such a
model, we challenged C57Bl/6 mice intranasally with a lethal dose
of influenza H1N1 A/PR/8/34 virus and tested different
treatment regimens in comparison to a vehicle control (placebo).
Figure 6 illustrates one typical result of several independent
experiments. If treatment with 60 mg iota-carrageenan per animal
was started on day 0 immediately after infection and repeated
twice daily during the course of the experiment (typically 15 days),
we noticed significantly increased survival rates in the iota-
carrageenan-treated group as compared to the placebo-treated
control group. In the particular experiment shown in Figure 6, by
day 15 after infection, 90% of the individuals in the placebo group
had succumbed to the infection whereas 70% of the iota-
carrageenan group had survived. In line with this result, survival
rates were also significantly increased if treatment was started one
day before infection (data not shown). Surprisingly, however,
treatment could be started also one or two days after infection and
still significantly increased survival rates. However, in contrast to
other experiments performed during the course of this study, the
difference between the 24 hours post-infection treatment schedule
and the control group did not quite reach significance.
Intrigued by this finding, we conducted a separate experiment
in which we determined the effect of intranasal iota-carrageenan
treatment on viral titer of infected mice. We infected 5 mice per
group as before and either started intranasal therapy with iota-
carrageenan or oral therapy with oseltamivir 24 and 48 hours
Figure 2. Effect of iota-carrageenan on influenza A-infected
primary human nasal epithelial cells. Primary human nasal
epithelial cells (HNep) cells grown in 96-well plates were infected with
A/PR/8/34 virus (5 PFU/cell) in the presence of iota-carrageenan at
concentrations indicated on the x-axis in mg/ml. 30 minutes after
infection, the inoculum was removed and medium containing iota-
carrageenan (black bars) or CMC (white bars) in indicated concentra-
tions added. Cell proliferation was determined with a Resazurin-based
in vitro toxicology assay. Samples were measured fluorometrically by
monitoring the increase in fluorescence at a wavelength of 590 nm
using an excitation wavelength of 544 nm. Values obtained from mock-
infected cells were set to 100%, and the values of cells infected in the
absence of polymer were set to 0% (y-axis). The bars represent the
mean of a quadruplicate experiment, the standard deviation is
indicated.
doi:10.1371/journal.pone.0014320.g002
Figure 3. Effect of iota-carrageenan on pandemic H1N1/2009
virus. Confluent monolayers of MDCK cells in 6-well plates were
washed free of protein-containing growth medium before use. An
equal volume of virus suspension mixed with iota-carrageenan,
containing 50 to 150 plaque-forming units, was added 5 to 10 min
later, and plates were incubated at room temperature for 60 min with
frequent shaking. The inoculum was removed and covered with an
overlay medium consisting of 0.6% agarose (3 ml) in Eagle minimal
essential medium and trypsin (2 mg/ml). Plates were incubated at 37uC
in a humidified atmosphere with 5% CO2. After 36 to 48 h, plaques
were stained with crystal violet and counted. The percentage of plaque
inhibition relative to infected control plates (y-axis) was determined for
each drug concentration (x-axis). The standard deviation of three
independent experiments is indicated.
doi:10.1371/journal.pone.0014320.g003
H1N1 Inhibition by Carrageenan
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mice were sacrificed 48 or 120 hours post infection and after
semi-daily therapy and viral titers were determined from pooled
specimens derived from the nasal cavity and lung by plaque
assays. As shown in Figure 6B, intranasal treatment of mice with
iota-carrageenan results in an immediate reduction of viral
particles in the nasal cavity 2 days and even more pronounced 5
days post infection, in the same order of magnitude as the
neuraminidase inhibitor oseltamivir. Conversely, while we could
not determine a titer reduction in the lung 48 hours post infection
(i.e. 1 day treatment) in the iota-carrageenan-treated group, we
could clearly show a strong reduction of viral particles in the
lungs of iota-carrageenan-treated mice 5 days post infection as
compared to the control group (Figure 6B). Importantly, iota-
carrageenan treatment seemed to be as efficient as an oseltamivir
therapy and as before, we could see a benefit with respect of viral
particle reduction in the nose and lung even if therapy was started
as late as 2 days post infection. Intranasal therapy of infected
mice with iota-carrageenan results in a survival benefit for mice
and seems to be a direct consequence of a reduction in viral
particles present in the nose and consequently in the lung at later
time points of the infection, respectively.
Oseltamivir and iota-carrageenan synergistically promote
survival of mice in a therapeutic setting starting as late as
48 hours post infection
To further explore the therapeutic potential of iota-carrageen-
an, we tested a combination with oseltamivir in the lethal infection
model of C57Bl/6 mice but with a ten times higher virus dose as
compared to the experiment shown in Figure 6. The treatment
consisted of an intranasal application of iota-carrageenan (60 mg/
animal/day in 0.5% NaCl) and an oral administration of
oseltamivir (10 mg/kg/day in 5% sucrose). Treatment was started
48 hours post infection and repeated twice daily until the end of
the experiment. Groups receiving oral doses of oseltamivir were
treated for five days with this drug according to protocol, and
thereafter received only iota-carrageenan and placebo intranasally
as before, respectively. While iota-carrageenan alone in the
particular experiment shown in Figure 7 supported the survival
of infected animals at significantly increased rates, treatment with
oseltamivir alone did not quite result in significantly higher
numbers of survivors as compared to the placebo group. However,
in other but similar experiments, oseltamivir monotherapy for five
days at the same dose was efficacious, significantly and comparable
to iota-carrageenan, if given 24 or 48 hours post infection (data
Figure 4. Binding of H1N1 influenza virus to iota-carrageenan. (A)-(F). Alexa Fluor 488-conjugated H1N1 influenza virus (H1N1-A488) was
incubated with iota-carrageenan-coated agarose beads (iota-beads) or control beads for 30 min at room temperature and visualized microscopically.( A )
Bright field picture ofiota-beads, showingno green auto-fluorescence(B).(C) Control agarosebeads incubated with H1N1-A488do not facilitateunspecific
virus binding. (D) Iota-beads incubated with H1N1-A488 demonstrates binding of virus to iota-carrageenan as evidenced by bright green staining of iota-
beads. (E) Binding of H1N1-A488 to iota-beads is inhibited in the presence of iota-carrageenan (400 mg/ml), but is not abolished in the presence of CMC
(400 mg/ml) (F). Scale bar =100 mm. (G) FACS analysis of MDCK cells incubated with H1N1-A488 in the presence of iota-carrageenan (400 mg/ml) (H) or
control polymer CMC (400 mg/ml) (I) showing that binding of H1N1-A488 to cognate receptors is inhibited by iota-carrageenan but not CMC.
doi:10.1371/journal.pone.0014320.g004
H1N1 Inhibition by Carrageenan
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treatments showed the same effects, namely, significantly increased
survival rates as compared to a monotherapy with either iota-
carrageenan or oseltamivir.
Discussion
In this report we demonstrate that iota-carrageenan, a
biopolymer derived from red seaweed, is a potent inhibitor of
influenza virus infectivity in vitro and in vivo. The report describes
cell culture studies, demonstrates the antiviral activity of iota-
carrageenan in mouse influenza infection models and proposes a
mode of action.
The antiviral activity of iota-carrageenan against several virus
types other than influenza has been studied more than 20 years
ago. Antiviral activity was found against herpes simplex virus type
(HSV) 1 and 2 at an IC50 of 2 and 10 mg/ml, respectively [28]. In
the same report, iota-carrageenan was found ineffective against
measles virus, adenovirus type 5, poliovirus and vesicular
stomatitis virus. Our results indicate that iota-carrageenan is
active against influenza A viruses at ten times lower concentrations
when compared with HSV-1 in a standard plaque reduction assay
(Table 1). This is comparable to our in vitro data of human
rhinoviruses [40], but does not reach the low effectivity dosage
range that has been described for papillomaviruses [38]. Both iota-
and kappa-carrageenan protected MDCK cells from virus-
induced cell death at an MOI of 0.01 (Figure 1A–B) in a dose-
dependent manner. Moreover, maintenance of MDCK cells in the
presence of iota-carrageenan up to 96 hours post infection with
H1N1 also resulted in a dramatic reduction of viral titers by 2-4
logs, indicative of a protective effect of iota-carrageenan with
regard to the spread and release of viral particles from previously
infected MDCK cells (Figure 1C–F). However, an increased
amount of input virus gradually reduces the protective effect.
Therefore, we conclude that the antiviral effect of carrageenan is
dependent on the relative amount of input virus in both cases. The
data support the hypothesis that iota-carrageenan possesses
antiviral activity due to direct interaction with the viruses.
To rule out tissue culture artefacts, we tested the antiviral
activity of iota-carrageenan against influenza in primary HNep
cells. The virus-induced CPE indirectly assessed by measuring cell
proliferation showed that iota-carrageenan promoted cell survival
at a concentration as low as 0.5 mg/ml (Figure 2). When compared
to MDCK cells (compare Figure 1 with Figure 2), we found that
iota-carrageenan showed a stronger antiviral effect on HNep cells.
Since HNep cells are sensitive to trypsin, the assay was carried out
Figure 5. Effect of iota-carrageenan on H1N1 virus adsorption and internalization. (A) Adsorption. H1N1 virus was added to MDCK cells in
the presence of different concentrations of iota-carrageenan or control polymer carboxymethylcellulose (CMC). After viral adsorption for 1 h at 4uC,
cells were washed and the number of cell-bound infectious viral particles determined by plaque assay; red bar 400 mg/ml, orange bar 4 mg/ml iota-
carrageenan, black bar 400 mg/ml, grey bar 4 mg/ml CMC. (B) Adsorption/Internalization. H1N1 virus was added to MDCK cells and adsorbed for 1 h at
4uC. Cells were washed and allowed to internalize virus in the presence or absence of different concentrations of iota-carrageenan or CMC for 1 h at
37uC. Subsequently, internalized infectious viral particles were determined by plaque assay. (C) Immunofluorescent visualisation of virus adsorption in
the presence of iota-carrageenan or CMC. 1 h post adsorption at 4uC, cells were stained after 1 h at 37uC with a mouse anti-NP antibody. (D)
Adsorption/Internalization. H1N1 was added to MDCK cells and adsorbed for 1 h at 4uC. Cells were washed and allowed to internalize virus in the
presence of iota-carrageenan or CMC for 1 h at 37uC. Compare the bright green stainings in Figure 5D indicative of productive infection to 5C, where
no green fluorescence is detected at high iota-carrageenan concentration.
doi:10.1371/journal.pone.0014320.g005
H1N1 Inhibition by Carrageenan
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is therefore caused by a single replication cycle. Consequently,
iota-carrageenan strongly inhibits the infection of HNep cells and
the subsequent first round of infection, but would be less effective
on cells already infected.
Importantly, iota-carrageenan had a similar antiviral effect on
H1N1 and H3N2 virus infection of MDCK cells and Vero cells,
respectively (data not shown). Since Vero cells have been
previously described to be deficient in INF gene expression [43],
the antiviral effect of iota-carrageenan is clearly not dependent on
interferon. Collectively, the data obtained on MDCK, Vero and
HNep cells suggest that iota-carrageenan interferes with viral
replication at a very early stage of viral infection, i.e. viral
adsorption and entry. Although iota-carrageenan binds to the
cellular surface only weakly, its antiviral effect might be due to
coating of cellular structures usually required for viral binding to
its cognate receptors. In order to visualize this, we fluorescently
labelled H1N1 virus and demonstrated that H1N1 directly binds
to iota-carrageenan-coated agarose beads. Binding to iota-
carrageenan was specific as it could be abolished in the presence
of excess iota-carrageenan but not control polymer (Figure 4).
When we studied the binding of fluorescently-labelled virus to
MDCK cells by FACS, only iota-carrageenan specifically inhibited
binding of labelled virus to cells (Figure 4). These results support
the hypothesis that iota-carrageenan interferes with virus adsorp-
tion to the cells. When MDCK cells were treated with iota-
carrageenan after adsorption of influenza virus to cells, we did not
observe plaque reduction as well as reduction of the signal when
stained with a NP-specific antibody, respectively. Therefore, iota-
carrageenan does not prevent the virus from being internalized
once it successfully binds to its receptor. In contrast, when iota-
carrageenan was already present during viral adsorption, a strong
reduction in plaque counts was observed and no signal could be
detected in immunofluorescence stainings for influenza-specific
NP protein (Figure 5). These findings lead us to the conclusion that
the antiviral effect of iota-carrageenan differs in dependence of the
virus. Recent data obtained with Dengue virus showed that
carrageenan may interfere not only with adsorption of virus to cells
but also block the fusion event leading to uncoating of the
nucleocapsid [36]. In contrast, our data obtained with influenza
virus demonstrate that iota-carrageenan exerts its antiviral effect
by effectively inhibiting virus adsorption to host cells and hardly
seems to interfere with later stages of the viral life cycle.
The recent outbreak of the pandemic (H1N1) 2009 virus
continues to expand in humans particularly in people at risk, such
as elderly or immuno-compromised individuals [44]. Thus, it was
important to determine whether iota-carrageenan has a similar
effect against the current pandemic (H1N1) 2009 virus strain. As
shown in figure 3, iota-carrageenan is highly active against the
Figure 6. Therapeutic efficacy of iota-carrageenan against
H1N1 influenza virus in a lethal mouse infection model. (A) Ten
mice per group were intranasally infected with 8.7610
2 PFU H1N1 A/
PR/8/34 viral particles at day 0. Intranasal therapy twice daily with 60 mg
iota-carrageenan in 0.5% NaCl or placebo (blue) started on the same
day as infection (black), 24 h post infection (poi) (orange), or 48 h poi
(green), and was performed twice daily for the entire experiment. P
values were calculated by a Log-rank (Mantel-Cox) test. Asterisk,
p,0.05, double asterisk p,0.01. (B)-(C). Determination of viral titers
from nose (B) and lung (C) specimens. Five mice per group were
intranasally infected at day 0 as before. The group receiving placebo
(blue) was compared to groups receiving intranasal therapy with iota-
carrageenan or oral therapy with oseltamivir (10 mg/kg/day in 5%
sucrose) starting 24 (orange or light grey) and 48 hours (green or dark
grey) post infection until groups of mice were sacrificed at day 2 and 5
days, respectively. Subsequently, nose and lung specimens of animals
from each experimental group and time point were pooled and viral
titers determined by plaque assays on MDCK cells at two different
dilutions. Bars represent the mean6SEM.
doi:10.1371/journal.pone.0014320.g006
Figure 7. Efficacy of iota-carrageenan in mice in comparison to
oseltamivir. Ten mice per group were intranasally infected with
8.7610
3 PFU H1N1/PR/8/34 viral particles at day 0 and therapy started
48 h poi (blue indicates the placebo treatment). In addition to the
group with intranasal treatment twice daily with 60 mg iota-carrageen-
an (green), a group of mice also received an oral dose of oseltamivir
(10 mg/kg/day in 5% sucrose) (grey) twice daily for 5 days, and
accordingly in combination with iota-carrageenan (red). P values were
calculated by a Log-rank (Mantel-Cox) test. Survival was monitored daily
for 15 days. Asterisk, p,0.05; triple asterisk p,0.001.
doi:10.1371/journal.pone.0014320.g007
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A/Aichi/2/68 H3N2 virus while inhibition of the A/PR8/34
H1N1 virus required five times higher concentrations of iota-
carrageenan (see Table 1). Given that pandemic H1N1/2009 virus
might persist in the population for several decades, it is of great
importance to have an effective treatment alternative with iota-
carrageenan, which might become very useful in case resistencies
of pandemic H1N1/2009 against the neuraminidase inhibitors
oseltamivir or zanamivir develop.
Mice are a well accepted animal model for the development of
antiviral compounds against influenza [42]. The susceptibility of
mice to pandemic (H1N1) 2009 virus has been shown to be limited
[45]. Consequently, we referred to established mouse models
based on known influenza virus strains. Data obtained with A/
Aichi/2/68 virus in a non-lethal animal model indicated that
therapy with iota-carrageenan indeed had a positive effect on
animal weight during infection (data not shown). Encouraged by
these results we switched to a lethal mouse model based on the A/
PR/8/34 virus. In this model, mice were infected intranasally with
a lethal dose of virus without the utilization of narcosis. This
procedure ensured that virus and the therapeutic solution were
applied to the nose and not directly to the lung. As shown in
Figure 6A, semi-daily intranasal treatment with a 1.2 mg/ml iota-
carrageenan solution resulted in significant improvements of
survival rates. While mice showed the best survival rate when
treatment was started immediately after infection, we observed
that iota-carrageenan treatment significantly promoted survival of
infected animals even when treatment was started as late as
48 hours after infection. There was no statistical difference
between mice whose treatment was started 24 hours or 48 hours
after infection. Statistical power calculations of the experiments
revealed that an unethically large population size would be
necessary to determine a statistical difference between these two
treatment groups.
Guided by our in vitro data which clearly suggest a reduction of
viral particles released from infected cells in the presence of iota-
carrageenan, we predicted that the same would hold true in the in
vivo infection model thereby arguing that the significantly
increased survival rate in the iota-carrageenan-treated group
could be attributed to a reduction of viral particles present in the
animals. To specifically address this issue, we performed another
animal experiment in which we sacrificed animals at certain time
points post infection (48 and 120 hours) and semi-daily treatment
with intranasal iota-carrageenan or oral oseltamivir. Importantly,
we started the therapy 24 or 48 hours post infection as to account
for a realistic treatment regimen for future patients thereby
assuming that patients would most likely start therapy shortly after
realizing first signs of a flu infection (i.e. 24–48 hours post
infection). As iota-carrageenan was applied intranasally, we were
obviously interested to determine the viral titer within the nose and
reasoned that a reduction in the upper respiratory tract by iota-
carrageenan treatment should consequently translate into less virus
spreading from the upper respiratory tract to the lungs (from
which the animals ultimately die due to severe lung inflammation).
As summarized in Figure 6B, we were able to convincingly
demonstrate that application of iota-carrageenan to the nose seems
to almost instantaneously translate into a reduction of viral
particles in the nose, i.e. 48 hours post infection and one semi-
daily therapy starting 24 hours after the initial infection. This
effect got more pronounced 5 days after the initial infection, even
when we started therapy 48 hours thereafter (i.e. semi-daily
therapy for 3 days). As for viral spread to the lungs (Figure 6C), we
were not able to see a titer reduction in the iota-carrageenan-
treated group at the 48 hour sampling point, in sharp contrast to
the orally treated oseltamivir group. However, at the second
sampling point 5 days post infection, iota-carrageenan-treated
animals had dramatically reduced lung titers as compared to the
placebo group and in the same order as the oseltamivir group.
Taken together, we propose that intranasal iota-carrageenan
treatment within a short time frame very efficiently counteracts
viral replication in the upper and spread to the lower respiratory
tract thereby providing a rationale as to why intranasal iota-
carrageenan treatment translates into a survival benefit as opposed
to placebo-treated animals. Those experiments do not sufficiently
address the question if the survival benefit of iota-carrageenan-
treated animals is due solely to a reduction of viral particles
spreading from the nose to the lung, or if other effects also
contribute that have not been addressed so far. Iota-carrageenan
has a molecular weight above 500 KDa, does not to cross mucosal
membranes and did not show any inhibitory or stimulatory effects
on a panel of immune cells (data not shown). We conclude that
due to a direct interaction of virus with polymer, binding of virus
to cells is hindered. Consequently, we speculate that the
subsequent viral replication-induced innate response of the host
is reduced and the survival of the animals is promoted. This is
further substantiated by our own findings in an exploratory study
in volunteers with early symptoms of the common cold [61], in
which intranasal administration of iota-carrageenan reduced the
symptoms of common cold (p=0.046), viral load in nasal lavages
(p=0.009), and amongst other cytokines also IL-8. However, it is
difficult to assess if that finding is a direct or indirect effect in
patients and clearly awaits further experimental analysis in future
clinical trials.
In order to further substantiate the above finding, we increased
the viral dose 10-fold and compared the antiviral efficacy of iota-
carrageenan to oseltamivir and a combination of both drugs,
respectively (Figure 7). The results of the experiment suggest that
iota-carrageenan promotes survival of influenza A-infected mice
even when treatment is started after 48 hours and the viral dose
increased 10-fold when compared to Figure 6A. There was no
statistically significant difference between the treatments with iota-
carrageenan and oseltamivir alone. However, when we combined
iota-carrageenan and oseltamivir and started the treatment
48 hours post infection, 60% of the mice survived the lethal
influenza dose. This result suggests that iota-carrageenan and
oseltamivir show additive therapeutic effects when given in
combination up to 48 hours post infection in mice.
The therapeutic use of neuraminidase inhibitors is broadly
described in the literature. As reviewed by Burch et al. [46], the
overall benefit of neuraminidase inhibitors in influenza virus-
infected adults is primarily seen in a reduction of the average time
period between the occurrence of the first disease symptoms of
infection and the beginning of symptom alleviation in influenza
virus-infected adults. For example, the administration of the
antiviral drug zanamivir to infected patients of the non-risk adults
group may reduce the median value for the time interval to
detectable symptom alleviation by 0.57 days, while the adminis-
tration of oseltamivir achieves a reduction by 0.55 days. These
data suggest that there may be a need for improved therapeutic
strategies based on compounds such as iota-carrageenan. Of
concern, however, is that widely-used monotherapy with oselta-
mivir for the treatment of seasonal influenza has already selected a
considerable proportion of resistant variants among circulating
influenza A (H1N1) strains [46–48]. Rapid global dissemination of
a H1N1 strain carrying a resistance-conferring neuraminidase
(NA) gene with an H274Y amino acid substitution occurred
during the 2007/2008 flu season [46,49] similar to the previously
observed emergence and fast spread of amantadine-resistant
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pointing to a reduced viability of H274Y-mutant strains [50,51],
recent clinical isolates showed an unimpaired replication potential
in vitro and full virulence in vivo [52–55]. However, the seasonal
H1N1 strain circulating since 2008 differs at several positions in
the NA gene other than H274Y and is therefore considered as a
natural variant of previous strains [56,57]. As the influenza virus
life cycle critically depends on a balance between available
receptor sites (neuraminidase) and receptor binding (hemaggluti-
nin), the new variant may have emerged by selection of a
compensatory co-mutation in the hemagglutinin gene to acquire
full virulence [9,56].
Polysaccharides and in particular carrageenans were found to
be potent antiviral agents against certain viruses. The antiviral
effects of carrageenans were of limited practical importance so far,
most likely because carrageenans are high-molecular weight
components making it unlikely that they pass the different barriers
of the body or even the cell membrane. However, these
characteristics do not rule out local applications. A recent study
with Carraguard, a carrageenan-based compound developed by
the Population Council, did not show efficacy in prevention of
vaginal transmission of HIV [26]. The authors conclude that low
acceptance of gel use could have compromised the potential to
detect a significant protective effect of Carraguard. In contrast to
influenza viruses, HIV causes a persistent systemic infection that is
usually not cleared by the immune system of the organism.
Therefore, an incomplete protective effect at the entry site of the
virus might lead to full blown HIV infection that is inaccessible to
treatment with an antiviral polymer.
The results of our animal experiments allow the speculation that
treatment with iota-carrageenan reduced the spreading of
influenza virus in surface epithelia of infected animals and thereby
provided sufficient benefit for animals to promote survival. In
conclusion, our results suggest that iota-carrageenan is safe and
effective in treating influenza infection in an animal model.
Moreover, given that a iota-carrageenan-containing nasal spray is
already marketed in Europe and has successfully been tested in an
exploratory trial for treating common cold in humans [61], iota-
carrageenan is also a promising antiviral candidate for the
prophylaxis and treatment of influenza virus infections and should
be tested for prevention and treatment of influenza A in clinical
trials in humans.
Materials and Methods
Compounds
Kappa-carrageenan and iota-carrageenan were purchased from
FMC Biopolymers (Philadelphia, PA). The dry polymer powders
were dissolved in cell culture water (PAA, Austria) to a final
concentration of 0.4%. This stock solution was sterile filtered
through a 0.22 mm filter (Sarstedt, Germany) and stored at 4uC
until use. The identity and purity (.95%) of carrageenan subtypes
was confirmed by NMR analysis as described elsewhere [58]. It
should be noted that commercially available batches of lambda-
carrageenan contained up to 30% of iota- and/or kappa-
carrageenan and others. Therefore, we excluded lambda-carra-
geenan preparations in this study. Oseltamivir was extracted from
Tamiflu capsules (Roche, Switzerland).
Cells and viruses
Madin-Darby canine kidney (MDCK) cells were obtained from
the American Type Culture Collection (Manassas, VA) and grown
in DMEM supplemented with 10% fetal calf serum (FCS; PAA,
Austria). Human nasal epithelial cells (HNep) were obtained from
PromoCell GesmbH (Heidelberg, Germany) and cultivated in
airway epithelial cell growth media (PromoCell). Vero (embryonic
African green monkey kidney) cells were purchased from the
American Type Culture Collection (ATCC; Manassas, Va.) and
grown in serum-free medium (Invitrogen, Darmstadt Germany).
Viruses A/PR/8 (H1N1) and A/Aichi/2/68 (H3N2) were
purchased from ATCC. Pandemic H1N1/2009 Virus A/Regens-
burg/D6/09/H1N1 was kindly provided by Stephan Becker,
University of Marburg, Germany. All influenza viruses were
propagated in MDCK cells.
Anti-influenza activity
Anti-influenza virus activity was evaluated by plaque reduction
assays. Confluent monolayers of MDCK cells in six-well tissue
culture plates were inoculated with 70-120 PFU of virus per well.
After 60 min, the inoculum was removed and the test medium was
added. MDCK cells inoculated with influenza A viruses were
incubated under 100% humidity and 5% CO2 in a 0.5% agarose
medium containing 0.001% of 2 mg of trypsin per ml for 2 days at
35uC. The cells were stained with 0.005% crystalviolet solution
and the plaque numbers were counted. The 50% inhibitory
concentrations (IC50s) were determined as the concentrations
required to reduce the number of plaques to 50% of the number in
wells containing no compounds.
The 50% tissue culture infectious dose (TCID50) was deter-
mined in MDCK cells with 10-fold serially diluted viruses
incubated at 37uC for 72 hours. Virus titers in 50% tissue culture
infectious doses (TCID50)/ml were determined according to Reed
and Muench [59].
CPE inhibition assays
For determination of antiviral activity, a CPE inhibition assay
was performed. MDCK cells were seeded in tissue culture plates
24 hours prior to the experiments. At 80% confluence cells were
infected with inoculums at defined amounts of input virus
(TCID50/cell). In order to test whether the polymers can inhibit
viral infection the cells were infected with virus in the presence or
absence of polymer. For determination of virus-induced reduction
in cell viability the cell metabolism was measured with an
alamarBlue assay (AbD Serotec, Duesseldorf, Germany). The
relative fluorescence at 544 nm (emission wavelength 590 nm) was
determined in an Omega reader (BMG Labtech, Offenburg,
Germany).
Relative cell survival in the presence of inhibitors was calculated
by setting mock-infected cells to 100% survival and cells infected
without inhibitor to 0% survival.
Alexa Fluor 488 labelling of virus
Labelling of virus was adapted from a protocol described
elsewhere [60]. Briefly, A/PR8/34 virus was grown in MDCK
cells and concentrated to 10
5 HAU via sucrose gradient
purification. 1610
4 HA units of virus in a given volume were
incubated with 1:10 of 1.0 M sodium bicarbonate pH 9. Alexa
488 was dissolved in 200 ml CMS to a final concentration of 5 mg/
ml and was added in a ratio of 0.005 mg/HAU. The virus-Alexa
mixture is wrapped into tinfoil and placed on a rotation mixer for
1 hour. Afterwards, the sample is dialyzed against PBS at 4uC. HA
titre was controlled via HA test and infectious particles were
determined by plaque assay to be 4*10
8 pfu/ml.
Immunocytochemistry
Iota-carrageenan beads (#02893) were provided by BioScience
Beads Division (West Warwick, RI). Beads were washed with PBS
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conjugated Influenza H1N1 PR8/34 virus. Alternatively, beads
were pre-incubated with 400 mg/ml iota-carrageenan, washed and
incubated with the conjugated virus. The beads were examined in
a Nikon Diaphot Fluorescence Microscope with a 61001 filter (D/
F/PI; C 121798). Images were taken by a CCD-camera and
analysed by Nikon NIS elements. The virus attached to the beads
showed bright green staining. As negative control beads were
analysed without virus incubation.
MDCK cells were grown in chamber slides in DMEM medium
with 10% FCS, washed in medium and incubated for the
adsorption experiment with a mixture of either iota-carrageenan
(400 or 4 mg/ml) and H1N1 (MOI=1) or CMC (400 or 4 mg/ml)
and H1N1 virus (MOI=1) for 1 h at 4uC in medium. For the
adsorption/internalization experiment, MDCK cells were incu-
bated with virus for 1 h at 4uC prior to incubation with iota-
carrageenan or CMC (1 h, 37uC). For both experiments cells were
washed afterwards with medium and fixed with 1% formaldehyde.
Cells were permeabilized with 0.3% TritonX-100, 10% FCS in
PBS for 15 min at RT, incubated with anti-NP in PBS with 10%
FCS, 0.1% Tween20 (dilution: 1:200; mouse anti-influenza A
(anti-NP), AbD Serotec, 0300-0234) for 1 h at RT, washed with
PBS with 10% FCS, 0.1% Tween20 and then incubated with an
anti-mouse Alexa 488-conjugated secondary antibody (Invitrogen,
Germany) diluted 1:200 in PBS with 10% FCS, 0.1% Tween20 for
1 h at RT. Cells were examined microscopically by the same
equipment as described above. As negative controls cells without
any treatment, cells with primary or secondary antibody only, and
cells without virus-incubation but antibody treatment were used.
All negative controls showed no staining (not shown).
FACS analysis
For FACS analysis, 1610
6 MDCK cells per sample were used.
Cells were detached with 0.5 mM EDTA, incubated with H1N1-
A488 (MOI=1) in the presence (or absence) of iota-carrageenan
and CMC as control polymer (each 400 mg/ml), washed with PBS,
fixed with 1% formaldehyde and examined directly afterwards
with a BD-FACSCalibur and analysed with WinMDI2.9.
Negative controls included cells only and cells with free Alexa488
(not shown).
Ethics Statement
All animals were handled in strict accordance with the
guidelines of the ‘‘European Convention for the Protection of
Vertebrate Animals used for Experimental and other Scientific
Purposes’’ and the Austrian law for animal experiments (BGBl. Nr.
501/1989 idF BGBl. I Nr.162/2005). All experimental procedures
were discussed and approved by the Veterinary University of
Vienna institutional ethics committee and performed under the
Austrian Federal Ministry of Science and Research experimental
animal license numbers BMWF-68.205/0130-II/10b/2008 and
BMWF-68.205/0135-II/10b/2009.
Pathogenicity and lethality in C57BL/6 mice
All mice were maintained under standard laboratory conditions
in the animal facility of the Veterinary University of Vienna. To
determine the 50% mouse lethal dose (MLD50) groups of 10
female 6-week-old C57BL/6 mice (Charles River Laboratories,
Sulzfeld, Germany) were intranasally inoculated with 50 ml of 10-
fold serial dilutions of A/PR8/34 (H1N1) virus in tissue culture
medium without narcosis. The MLD50 values were calculated
after a 14-days observation period by the Reed-Muench method
[59]. The determined values for 1 MLD50 of the viruses were
expressed as PFU. To determine the viral titer of lung and nose
samples, tissue samples were snap-frozen upon dissection and
subsequently homogenized in serum-free DMEM medium for
plaque reduction assays as described above.
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